Read More
Publications & Posters

Research that inspires, data that informs, and knowledge that empowers.

We are proud to contribute to the latest immunology and inflammation research through scientific publications and medical meetings.

December 2024

EVO756, an oral MRGPRX2 antagonist, is well-tolerated and demonstrates target engagement: Results from a Phase 1 Study

Sarbjit S. Saini, MD, Kelly Devine, RN, BSN, CCRP, Tahira Mirza, MBBS, CCRP, Kristin L. Chichester, MS, Janice Drew, MPH, Polina Bukshpun, Kelsey Santisteban, Dan Burge, MD
Presented at the 7th GA²LEN Global Urticaria Forum (Berlin, Germany), 2024

December 2024

EVO756 inhibits activation of MRGPRX2 in several in vitro models and correlates to human in vivo data

Sreya Bagchil, Jeegar Patel, Lorena Riol Blanco, Jamie L. Harden
Presented at the 7th GA²LEN Global Urticaria Forum (Berlin, Germany), 2024

May 2024

Transcriptional profiling of primary human-skin derived mast cell activation by various MRGPRX2 agonists and inhibition with EVO756

Sreya Bagchi, Jeegar Patel, Lorena Riol Blanco, Jamie L. Harden
Presented at American Association of Immunology (AAI), 2024

November 2023

EVO756 is a novel MRGPRX2 antagonist that potently inhibits human mast cell degranulation in response to multiple agonists – a potential treatment for CSU and beyond


Jamie L. Harden, Jelle Folkerts, See-Ying Tam, Stefan Frischbutter, Magda Babina4, Hans E. Hofland, Jeegar P. Patel, Marcus Maurer, and Stephen J. Galli
Presented at the Inflammatory Skin Disease Summit, 2023

November 2023

Role of MRGPRs in substance P signaling, itch, and mast cell activation


Yanek Jiménez-Andrade, Lilah Gmyrek, Jamie Harden, Jeegar Patel, Hans Hofland, Jin Mo Park, and Ethan A. Lerner

Presented at the World Congress on Itch, 2023

We have a range of chronic inflammatory disease programs currently in development.

See our pipeline